Brii Biosciences Limited (2137.HK) Comparison with companies in other sectors?

Brii Biosciences Limited has a share price of 732.06M. You can analyze Brii Biosciences Limited (2137.HK) competitors across different market sectors through stock heatmaps.

What are 2137.HK's NET and operating margins?

Brii Biosciences Limited (2137.HK) operating margin is around -7.36, and net profit margin is approximately -9.36 as of the latest reports.

In what way does 2137.HK's earnings per share (EPS) trend reflect its financial momentum?

Brii Biosciences Limited (2137.HK) EPS is -0.77 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Brii Biosciences Limited is -2.56, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Brii Biosciences Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Brii Biosciences Limited like P/E which is -2.50, P/B which is 0.48, and PEG which is 0.03. Compare them with sector averages to evaluate if the stock is priced fairly.

Brii Biosciences Limited

2137.HK•HKSE

Healthcare

Biotechnology

HK$1.97

HK$0.08(4.23%)

Brii Biosciences Limited (2137.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.77

P/E Ratio

-2.56

ROE

-0.18%

Net Margin

-9.36%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.44B

Shares OutstandingTotal number of shares issued

$732.06M

Book Value/ShareNet worth per share

$3.57

Revenue/ShareAnnual revenue per share

$0.07

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.77

Net MarginNet income as percentage of revenue

-936.08%

Operating MarginOperating income as percentage of revenue

-735.92%

ROEReturn on shareholders' equity

-18.42%

ROAReturn on total assets

-18.77%

ROCEReturn on capital employed

-15.19%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.31

Cash/ShareCash and equivalents per share

$3.19

FCF YieldFree cash flow as percentage of market cap

-17.83%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2137.HKFinancial Ratios Analysis details for 2137.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2137.HKSector Benchmarking details for 2137.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Brii Biosciences Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Brii Biosciences Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Brii Biosciences Limited's unique business strengths and challenges.

Key Financial Metrics for Brii Biosciences Limited

For Brii Biosciences Limited, essential financial indicators include EPS -0.77, PE -2.56, and ROE -0.18. These key ratios reveal insights into Brii Biosciences Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Brii Biosciences Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Brii Biosciences Limited

Metrics like Net Margin -936.08% and ROA -18.77% shed light on how well Brii Biosciences Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Brii Biosciences Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Brii Biosciences Limited

Using ratios such as P/B Ratio 0.48 and PEG Ratio 0.03, investors can assess whether Brii Biosciences Limited is appropriately valued based on its financials and growth potential. These figures, combined with Brii Biosciences Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Brii Biosciences Limited

Financial health indicators, such as Debt/Equity Ratio 0.01 and Cash Flow $-0.31, provide a snapshot of Brii Biosciences Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Brii Biosciences Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Brii Biosciences Limited

Investing in Brii Biosciences Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Brii Biosciences Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;